References
- Steensma D, Bennett J. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clinic Proc 2006; 81: 104–130
- Navarro I, Ruiz M A, Cabello C RA, Ferrer R, Hueso J, Martinez J, et al. Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients. Leuk Res 2006, e-pub ahead of print
- Deeg H J. Transplant strategies for patients with myelodysplastic syndromes. Curr Opin Hematol 2006; 13: 61–66
- Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393
- Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 2006; 47: 599–602
- Gupta V DA, Lipton J H, Hasegawa W, Chun K, Kamel-Reid S, Tsang R, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005; 11: 764–772
References
- Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, Soubeyran P. Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47: 603–611
- Sweetenham J. Diffuse large cell lymphoma: Risk stratification and management of relapsed disease. ASH Education Book. 2005; 252–259, Available from http://www.asheducationbook.org
- Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11–22
- Küppers R. Prognosis in follicular lymphoma—It's in the microenvironment. N Engl J Med 2004; 351: 2152–2153
- Rohatiner A, Gregory W, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
- Dave S, Wright G, Tan B, Rasenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
- Pagés F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654–2666
- Cunningham L, Chapman C, Dunstan R, Joske D JL. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 251–255
- Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interluekin-10 polymorphisms influence the clinical outcome of diffuse large cell lymphoma. Blood 2004; 103: 3529–3534
- Rothman N, Skibola C, Wang S, Morgan G, Lan O, Smith M T, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2005; 7: 27–38
References
- Radford K J, Vari F, Hart D N. Vaccine strategies to treat lymphoproliferative disorders. Pathology 2005; 37: 534–550
- Cambi A, Figdor C G. Levels of complexity in pathogen recognition by C-type lectins. Curr Opin Immunol 2005; 17: 345–351
- Vuckovic S, Gardiner D, Field K, Chapman G V, Khalil D, Gill D, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. J Immunol Meth 2004; 284: 73–87
- Clark G, Munster D, Yusuf S, Hart D N. Eighth leucocyte differentiation antigen workshop DC section summary. Cell Immunol 2005; 236: 21–28
- Vuckovic S, Fearnley D B, Gunningham S P, Spearing R L, Patton W N, Hart D NJ. Dendritic cells in chronic myelomonocytic leukaemia. Br J Haematol 1999; 5: 974–985
- Chaperot L, Perrot I, Jacob M C, Blanchard D, Salaun V, Deneys V, et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004; 34: 418–426
- Turtle C J, Brown R D, Joshua D E, Hart D N. DC in multiple myeloma immunotherapy. Cytotherapy 2004; 6: 128–137
- Flore F, Von Bergwett-Baildon M S, Drebber U, Beyer M, Popov A, Manzke O, et al. Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk Lymphoma 2006; 47: 613–622
References
- Landier W, Bhatia S, Eshelman D A, Forte K J, Sweeney T, Hester A L, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979–4990
- Partridge A H, Winer E P. Fertility after breast cancer; Questions abound. J Clin Oncol 2005; 23: 4259–4261
- Schover L R. Motivation for parenthood after cancer: a review. J Nat Cancer Inst Monographs 2005; 34: 2–5
- Stern C J, Toledo M G, Gook D A, Seymour J F. Fertility preservation in female oncology patients. Aus N Zeal J Obstet Gynaecol 2006; 46: 15–23
- Donnez J, Dolmans M M, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405–1410
- Seshadri T, Gook D, Lade S, Spencer A, Grigg A, Tiedmemann K, et al. Lack of evidence of disease contamination in cryopreserved ovarian tissue harvested from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 2006, in press
- Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann E J, et al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 623–627
- Goodwin P J, Ennis M, Pritchard K I, Trudeau M, Hood Nl. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365–2370
- Blumenfeld Z, Avivi I, Ritter M, Rowe J M. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc for Gynecol Investigation 1999; 6: 229–239
- Byrne J, Fears T R, Gail M H, Pee D, Connelly R R, Austin D F, et al. early menopause in long term survivors of cancer during adolescence. Am J Obstet Gynecol 1992; 166: 788–793
- Seshadri T, Hourigan M J, Wolf M, Mollee P N, Seymour J F. The effect of the “Hyper-CVAD” chemotherapy regimen on fertility and ovarian function. Leuk Res 2006; 30: 483–485
- Seymour J F. Ovarian tissue cryopreservation for cancer patients: who is appropriate?. Reprod Fertil Develop 2001; 13: 81–89
References
- Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786–3792
- Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
- Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835–1842
- Papageorgiou E S, Tsirigotis P, Dimopoulos M, Pavlidis N, Fountzilas G, Papageorgiou S, Economopoulos T. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Onco- logy Group. Euro J Haematol 2005; 75: 124–129
- Muller-Beissenhirtz H, Kasper C, Nuckel H, Duhrsen U. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol 2005; 84: 796–801
- Massoud M, Armand J P, Ribrag V. Procarbazine in haematology: an old drug with a new life?. Euro J Cancer 2004; 40: 1924–1927
- Chaar B T, Salem P, Petruska P J. Procarbazine for non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 637–640
References
- Pardoll D M. Spining molecular immunology into successful immunotherapy. Nat Rev 2002; 2: 227–238
- Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4: 401–411
- Kwak L W, Campbell M J, Czerwinski D K, Hart S, Miller R A, Levy R, et al. Induction of immune response in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl Med 1992; 327: 1209–1215
- Hsu F J, Benike C, Fagoni F, Liles T M, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphomas using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–58
- Hurvitz S A, Timmerman J M. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol 2005; 17: 432–440
- Stevenson F K. DNA vaccines and adjuvants. Immunol Rev 2004; 199: 5–8
- Ritchie D, Hermans I, Yang J, Walton J, Matthews K, Carter J, et al. Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma 2006; 47: 675–682
- Zitvogel L, Mayordomo J I, Tjandrawan T, DeLeo A B, Clarke M R, Lotze M T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines. J Exp Med 1996; 183: 87–97
- O'Neill D W, Adams S, Bhardway N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235–2245
- Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull D, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003; 171: 6275–6282
References
- Abou-Jawde R M, Sobecks R, Pohlman B, Rybicki L, Advani A, Sekeres M, Kalaycio M. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 2006; 47: 689–695
- Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig W D, Fischer J, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583–1589
- Cassileth P A, Harrington D P, Hines J D, Oken M M, Mazza J J, McGlave P, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988; 6: 583–587
- Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903
- Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy— the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872–881
- Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P P, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548–553
- Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569–3576
- Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
- Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14: 796–804
- Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
- Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004; 100: 441–454
- Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268–1274
- Juliusson G, Billstrom R, Gruber A, Hellstrom-Lindberg E, Hoglund M, Karlsson K, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 2005, in press
References
- Gorin N C, Estey E, Jones R J, Levitsky H I, Borrello I, Slavin S. New developments in the therapy of acute myelocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2000; 69–89
- Bastie J N, Balitrand N, Guillemot I, Chomienne C, Delva L. Cooperative action of 1alpha,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. Exp Cell Res 2005; 310: 319–330
- Wang Q, Harrison J S, Uskokovic M, Kutner A, Studzinski G P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005; 19: 1812–1817
- Wu-Wong J R, Nakane M, Ma J, Dixon D, Gagne G. Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells. Leuk Lymphoma 2006; 47: 727–732